BLR-200

BLR-200 is a synthetic peptide derived from the CCN3 protein, developed as an anti-fibrotic therapeutic. It is designed to address multiple disease-driving elements and redundancies in the pathways leading to fibrosis, particularly by targeting myofibroblasts—key scar-forming cells implicated in fibrotic diseases. Preclinical studies have shown that BLR-200 can reduce skin and lung fibrosis in models of systemic sclerosis (scleroderma) and interstitial lung disease by modulating molecular markers associated with fibrogenesis. The drug has received orphan drug designation from the US FDA for systemic sclerosis, reflecting its potential as a first-in-class therapy for this rare autoimmune condition[1][3][4][5][7][8][10].